In Heart Failure Patients, Spironolactone Linked to Reduced Risk of Dementia, Alzheimers Disease

A propensity score-matched analysis of data suggests use of spironolactone could reduce the 3-year risk of developing Alzheimer disease or dementia among patients with heart failure with reduced ejection fraction.

Related Keywords

United States ,Manhattan ,New York ,Stony Brook ,America ,Andreas Kalogeropoulos ,Cardiovascular Health Study ,Division Of Cardiology At Stony Brook Medicine ,Heart Society Of America ,Artery Risk Development In Young Adults Study ,Heart Society ,Stony Brook Medicine ,Atherosclerosis Risk ,Communities Study ,Coronary Artery Risk Development ,Young Adults Study ,Framingham Offspring Study ,Multi Ethnic Study ,Northern Manhattan Study ,Confidence Interval ,Hfsa ,Hfsa 2023 ,Spironolactone ,Cognitive Decline ,